Bicara Therapeutics (BCAX) to Release Quarterly Earnings on Tuesday

Bicara Therapeutics (NASDAQ:BCAX) will likely be issuing its quarterly earnings data before the market opens on Tuesday, February 11th. Analysts expect the company to announce earnings of ($0.30) per share for the quarter.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($0.46) by ($1.14). On average, analysts expect Bicara Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Bicara Therapeutics Price Performance

Shares of Bicara Therapeutics stock opened at $12.30 on Tuesday. The stock has a 50-day moving average price of $16.45. Bicara Therapeutics has a fifty-two week low of $11.10 and a fifty-two week high of $28.09.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on BCAX. TD Cowen started coverage on Bicara Therapeutics in a research report on Tuesday, October 8th. They set a “buy” rating on the stock. Rodman & Renshaw assumed coverage on Bicara Therapeutics in a research report on Tuesday, November 5th. They set a “buy” rating and a $48.00 target price on the stock. RODMAN&RENSHAW raised shares of Bicara Therapeutics to a “strong-buy” rating in a report on Tuesday, November 5th. HC Wainwright increased their price objective on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a report on Monday, January 27th. Finally, Stifel Nicolaus initiated coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They set a “buy” rating and a $47.00 target price for the company. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $43.75.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.